Ticagrelor 90mg Antiplatelet PCD Pharma Franchise

Brand Name

TICADOL-90 Tablet

Composition

Ticagrelor 90mg

Therapeutic Use

Prevention of thrombotic events in coronary artery disease

Size

10*14

Verified Exporter

Verified Seller

Trusted Pharma

Description

Ticagrelor 90mg Tablet contains Ticagrelor 90mg, an oral antiplatelet medicine belonging to the P2Y12 platelet receptor inhibitor class. It helps reduce platelet aggregation and the formation of harmful blood clots. Ticagrelor may be prescribed for eligible patients with acute coronary syndrome and certain other cardiovascular conditions when antiplatelet treatment is clinically indicated.

The medicine works by inhibiting platelet activation, helping reduce the risk of further atherothrombotic events in appropriately selected patients. It is commonly used as part of a clinician-directed treatment plan that may include aspirin and other cardiovascular risk-management measures. Treatment suitability, dosage and duration depend on the patient’s condition, bleeding risk, previous cardiovascular events and concurrent medicines.

CardianCare focuses on cardiac and diabetic healthcare products for doctors, pharmacists, distributors and pharmaceutical business partners. Businesses searching for a Ticagrelor 90mg Tablets manufacturer India can enquire about product availability, approved specifications, manufacturing-source details and applicable quality documentation.

For procurement teams evaluating a Ticagrelor 90mg Tablets manufacturer and supplier India, important considerations include composition accuracy, product authorization, batch traceability, packaging specifications, shelf life and commercial supply terms. The supplied product information identifies Synokem as the manufacturer; buyers should verify the current manufacturing and authorization details against the approved product documentation.

2. Key Ingredient:

Composition: Ticagrelor 90mg

Ticagrelor is an oral antiplatelet agent that acts on the P2Y12 receptor on platelets. It reversibly inhibits the binding and signalling of adenosine diphosphate (ADP), reducing platelet activation and aggregation.

Unlike medicines that inhibit platelet function through the same pathway irreversibly, ticagrelor has a reversible P2Y12 receptor action. Its antiplatelet effect can help reduce clot formation in patients for whom this treatment is indicated, but it also increases the risk of bleeding.

Businesses researching a Ticagrelor 90mg pharmaceutical company India should assess the approved composition, product authorization, manufacturing-source information, labelling and applicable quality documentation before procurement.

Companies seeking a Ticagrelor 90mg medicine manufacturer India should verify the manufacturer’s regulatory status, product approvals, batch documentation and relevant quality standards. The manufacturer and marketer should be identified separately wherever required by applicable labelling and regulatory rules.

3. Key Benefits

Platelet aggregation inhibition: Helps reduce platelet activation and aggregation in patients for whom antiplatelet therapy is indicated.

Cardiovascular risk management: May reduce the risk of certain atherothrombotic events in appropriately selected patients.

Targeted mechanism of action: Acts on the platelet P2Y12 receptor to inhibit ADP-mediated platelet activation.

Oral dosage form: Provides an oral treatment option for patients who are prescribed ticagrelor Tablets.

Role in combination therapy: May be prescribed with low-dose aspirin for selected cardiovascular indications under medical supervision.

Support for individualized treatment: Can form part of a broader cardiovascular plan that includes monitoring, lifestyle measures and other prescribed therapies.

The clinical benefit depends on the indication, treatment adherence, individual cardiovascular risk and bleeding risk. Ticagrelor is not a substitute for cholesterol management, and it should not be started or stopped without medical advice.

Pharmaceutical buyers searching for a Ticagrelor 90mg supplier India should verify product authenticity, current availability, storage requirements, shelf life and supporting documentation.

A Ticagrelor 90mg Tablet wholesaler and distributor India enquiry may include stock availability, minimum order quantities, delivery coverage, licensing requirements and applicable commercial terms.

Businesses seeking a Ticagrelor 90mg bulk supplier India should request a formal quotation and confirm batch traceability, packaging specifications, storage conditions and quality documentation.

A Ticagrelor 90mg pharmaceutical distributor India should verify product authorization, distribution eligibility and approved promotional information before beginning commercial activities.

4. How Does It Work?

Ticagrelor reversibly blocks the platelet P2Y12 receptor, which normally responds to ADP and contributes to platelet activation.

By inhibiting this receptor, ticagrelor reduces ADP-mediated platelet activation and aggregation. This makes platelets less likely to clump together and contribute to harmful clot formation.

Its action is antiplatelet rather than anticoagulant: it affects platelet function rather than directly inhibiting the blood-clotting factors targeted by anticoagulant medicines.

Because platelet function is reduced, bleeding can occur more easily or last longer. The prescriber must balance the potential cardiovascular benefit against bleeding risk and review any concurrent antiplatelet or anticoagulant therapy.

5. Directions for Use

Dosage: Take only as prescribed by a qualified doctor. The appropriate regimen depends on the clinical indication and the patient’s medical history.

Administration: Follow the approved product label and the prescriber’s instructions. Swallow the Tablet as directed.

Food instructions: Ticagrelor may generally be taken with or without food, subject to the approved product information.

Regular timing: Take doses according to the prescribed schedule. Do not change the dose or frequency independently.

Missed dose: Follow the patient information leaflet or ask a doctor or pharmacist. Do not take an extra dose to compensate for a missed one.

Treatment continuity: Do not stop treatment without medical advice. Premature discontinuation can increase the risk of cardiovascular events in some patients.

Before surgery or dental procedures: Inform the treating clinician that you take ticagrelor. Any decision to interrupt treatment must be made by the responsible healthcare professional.

Monitoring: Attend recommended follow-up appointments and report unusual bleeding, shortness of breath or other concerning symptoms.

The 90 mg strength is not appropriate for every patient or every stage of cardiovascular treatment. The prescriber must determine the suitable regimen and duration according to the approved indication and individual clinical circumstances.

6. Possible Side Effects

Possible side effects of ticagrelor include:

Bleeding or bruising more easily

Nosebleeds

Gastrointestinal discomfort

Shortness of breath (dyspnoea)

Dizziness in some patients

Important adverse reactions

Serious bleeding: Uncontrolled bleeding, vomiting blood, black or tarry stools, blood in urine or a sudden severe headache requires urgent medical assessment.

Shortness of breath: Breathlessness can occur during treatment. New, severe or worsening symptoms should be assessed promptly, particularly in patients with underlying heart or lung disease.

Slow heart rate or rhythm disturbances: Seek medical advice if fainting, significant dizziness or symptoms suggestive of an abnormal heart rhythm occur.

Allergic reactions: Facial or throat swelling, difficulty breathing or a severe rash requires emergency care.

Other abnormal bleeding: Report persistent bleeding, unusual bruising or any suspected internal bleeding to a healthcare professional.

This list is not exhaustive. Seek professional medical advice about persistent or concerning symptoms.

7. Safety Information

Medical supervision: Use only under the guidance of a qualified healthcare professional.

Contraindications: Ticagrelor should not be used in patients with active pathological bleeding or a history of intracranial haemorrhage, and it is contraindicated in serious hypersensitivity to the medicine or its ingredients. Follow the approved product information.

Bleeding risk: Inform the doctor about previous gastrointestinal bleeding, ulcers, bleeding disorders or unexplained bruising.

Surgery and procedures: Inform the surgeon, dentist and other treating professionals about ticagrelor use. Do not stop it independently, especially after a coronary event or stent procedure.

Heart rhythm: Tell the doctor about a history of slow heart rate, fainting or rhythm disorders.

Liver health: Inform the prescriber about significant liver disease. Severe hepatic impairment may make treatment unsuitable.

Kidney health: Tell the doctor about kidney disease and follow recommended clinical monitoring.

Pregnancy: Consult a doctor before use during pregnancy or when planning pregnancy. The clinician should assess the potential benefits and risks.

Breastfeeding: Seek medical advice before using ticagrelor while breastfeeding.

Drug interactions: Tell the doctor about all prescription medicines, over-the-counter products and supplements. Strong CYP3A inhibitors and inducers can significantly affect ticagrelor exposure. Anticoagulants, other antiplatelet medicines and NSAIDs can increase bleeding risk.

Aspirin combination: If ticagrelor is prescribed with aspirin, follow the prescriber’s specific instructions on the aspirin dose.

Storage: Store in the original packaging according to the approved product label, protected from excessive heat and moisture and out of children’s reach.

This information is educational and does not replace approved prescribing information or individualized medical advice.

8. B2B Pharmaceutical Business Enquiries

CardianCare focuses on cardiac and diabetic healthcare products and provides a contact point for pharmaceutical trade enquiries. Doctors, pharmacists, procurement teams, wholesalers, distributors and eligible business partners can contact the company to enquire about current product availability and applicable commercial arrangements.

Businesses researching a Ticagrelor 90mg PCD pharma franchise India opportunity should confirm directly whether the product and the relevant programme are available, including territory eligibility, partner requirements and applicable commercial terms.

For a Ticagrelor 90mg Tablets PCD pharma franchise enquiry, prospective partners may request details about product availability, minimum order quantities, licensing requirements, distribution eligibility and any applicable promotional support.

Companies exploring a Ticagrelor 90mg Tablet PCD franchise should verify the current programme and product availability before making investment or promotional commitments.

Businesses evaluating Ticagrelor 90mg third party manufacturing India services should first confirm whether the proposed company offers these arrangements. Due diligence should cover manufacturing authorization, applicable GMP compliance, product approvals, quality documentation and batch-release procedures.

A Ticagrelor 90mg Tablet third party manufacturer India enquiry should cover manufacturing-facility credentials, approved specifications, quality systems, packaging requirements, regulatory responsibilities and product traceability.

Companies investigating Ticagrelor 90mg contract manufacturing India should confirm service availability and discuss technical specifications, quality agreements, product authorization, regulatory responsibilities and commercial feasibility with the proposed manufacturing partner.

Contact CardianCare through its official website to enquire about current product availability, pharmaceutical distribution opportunities and applicable business arrangements. PCD franchise, third-party manufacturing and contract manufacturing services must be confirmed directly before being represented as available.

9. For More Information

For more information about TICADOL-90 Tablet (Ticagrelor 90mg), click here

Frequently Asked Questions

Ticagrelor is an antiplatelet medicine prescribed for certain cardiovascular conditions, including acute coronary syndrome in appropriate patients. The indication and treatment duration must be determined by a qualified healthcare professional.

The stated active ingredient is Ticagrelor 90 mg. It is a P2Y12 platelet receptor inhibitor that reduces ADP-mediated platelet activation and aggregation.

Ticagrelor reversibly inhibits the platelet P2Y12 receptor, reducing platelet activation and aggregation. This helps lower the tendency for platelets to contribute to harmful clot formation.

For appropriately selected patients, ticagrelor can reduce platelet aggregation and help lower the risk of certain atherothrombotic events. Its use depends on the clinical indication and an individualized assessment of bleeding risk.

Take it exactly as prescribed and follow the approved product label. Do not change the dose or stop treatment without medical advice.

Bleeding, easy bruising, nosebleeds and shortness of breath are among the possible side effects. Serious bleeding or severe breathing difficulties require prompt medical assessment.

Patients with active pathological bleeding, a history of intracranial haemorrhage or serious hypersensitivity to ticagrelor should not use it. Patients with significant liver disease, bleeding risks or heart rhythm concerns need careful medical assessment.

Ticagrelor is often prescribed with low-dose aspirin for selected indications. However, aspirin, anticoagulants, NSAIDs and other medicines affecting bleeding can increase bleeding risk. Follow the prescriber's instructions and do not add medicines independently.

Store it in the original packaging according to the approved product label, protected from excessive heat and moisture and out of children's reach.

Buyers should verify the active ingredient, strength, approved dosage form, product authorization, manufacturing source, batch documentation, shelf life, packaging and commercial terms. Distribution and manufacturing services should be confirmed directly with the relevant company.

Reviews

There are no reviews yet.

Be the first to review “Ticagrelor 90mg Antiplatelet PCD Pharma Franchise”

Your email address will not be published. Required fields are marked *

Enquiry Now
close slider

    Drop us a Line